These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 15515746)

  • 1. Value of technetium scintigraphy and iodine uptake measurement during follow-up of differentiated thyroid cancer.
    Caglar M; Tuncel M; Alpar R
    Ann Nucl Med; 2004 Sep; 18(6):479-82. PubMed ID: 15515746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery.
    Rubello D; Mazzarotto R; Casara D
    Eur J Nucl Med; 2000 Apr; 27(4):431-40. PubMed ID: 10805117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Tc-99m pertechnetate for remnant scintigraphy, post-thyroidectomy, and serum thyroglobulin and antithyroglobulin antibody levels in the patients with differentiated thyroid cancer.
    Aydin F; Sipahi M; Budak ES; Oner AO; Demirelli S; Erkilic M; Gungor F
    Ann Nucl Med; 2016 Jan; 30(1):60-7. PubMed ID: 26462671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postsurgical thyroid remnant estimation by (⁹⁹m) Tc-pertechnetate scintigraphy predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma.
    Giovanella L; Suriano S; Ricci R; Ceriani L; Anton Verburg F
    Head Neck; 2011 Apr; 33(4):552-6. PubMed ID: 20824809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
    Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
    J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical importance of technetium-99m-methoxyisobutylisonitrile (MIBI) scintigraphy in differentiated thyroid carcinoma patients with elevated thyroglobulin levels and negative I-131 scanning results.
    Küçük NO; Külak HA; Aras G
    Ann Nucl Med; 2006 Jul; 20(6):393-7. PubMed ID: 16922467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
    Lind P; Gallowitsch HJ
    Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnostic modalities in patients affected by differentiated thyroid carcinoma with high thyroglobulin levels and total body Iodium-131 negative: PET/CT use after recTSH].
    Biscontini G; Possa M; Sara R; Milella M; Rossetti C
    Minerva Endocrinol; 2004 Dec; 29(4):151-60. PubMed ID: 15765025
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Giovanella L; Paone G; Ruberto T; Ceriani L; Trimboli P
    Endocrinol Metab (Seoul); 2019 Mar; 34(1):63-69. PubMed ID: 30784242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical importance of anti-thyroglobulin auto-antibodies in patients with differentiated thyroid carcinoma: comparison with 99mTc-MIBI scans.
    Küçük ON; Aras G; Kulak HA; Ibiş E
    Nucl Med Commun; 2006 Nov; 27(11):873-6. PubMed ID: 17021427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
    Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioiodine whole-body scans, thyroglobulin levels, 99mTc-MIBI scans and computed tomography: results in patients with lung metastases from differentiated thyroid cancer.
    Küçük ON; Gültekin SS; Aras G; Ibiş E
    Nucl Med Commun; 2006 Mar; 27(3):261-6. PubMed ID: 16479246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compliance with follow-up and the informative value of diagnostic whole-body scan in patients with differentiated thyroid carcinoma given recombinant human TSH.
    Cohen O; Dabhi S; Karasik A; Zila Zwas S
    Eur J Endocrinol; 2004 Mar; 150(3):285-90. PubMed ID: 15012612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment.
    Pacini F; Capezzone M; Elisei R; Ceccarelli C; Taddei D; Pinchera A
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1499-501. PubMed ID: 11932271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience.
    Giusti M; Zoccola R; Guazzini B; Molinari E; Valenti S; Villa G; Bertolazzi L; Minuto F
    Minerva Endocrinol; 2003 Sep; 28(3):191-203. PubMed ID: 14605601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 99mTc-sestamibi and 131I whole-body scintigraphy and initial serum thyroglobulin in the management of differentiated thyroid carcinoma.
    Ng DC; Sundram FX; Sin AE
    J Nucl Med; 2000 Apr; 41(4):631-5. PubMed ID: 10768563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sufficiency of a Single Negative Thyroglobulin Standard for Judging the Success of Ablation in Low- and Intermediate-risk Differentiated Thyroid Cancer: A Retrospective Study.
    Long Y; Jin J; Zhang W
    Endocr Metab Immune Disord Drug Targets; 2024; 24(10):1204-1214. PubMed ID: 38192150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of technetium-99m methoxisobutylisonitrile imaging in differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 Na scintigraphy, and serum thyroglobulin quantitation.
    Dadparvar S; Chevres A; Tulchinsky M; Krishna-Badrinath L; Khan AS; Slizofski WJ
    Eur J Nucl Med; 1995 Nov; 22(11):1330-8. PubMed ID: 8575487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.
    Iwata M; Kasagi K; Misaki T; Matsumoto K; Iida Y; Ishimori T; Nakamoto Y; Higashi T; Saga T; Konishi J
    Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):491-8. PubMed ID: 14666387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negative remnant
    Lan W; Gege Z; Ningning L; Qiang W; Lin B; Qingjie M; Bin J
    Ann Nucl Med; 2019 Feb; 33(2):112-118. PubMed ID: 30374858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.